NCT03106623

Study of ONO-8577 in Patients With Overactive Bladder

Phase 2a Exploratory, Randomized, Double-blind, Parallel-group Study of ONO-8577 Compared to Combination of Solifenacin Succinate/ Mirabegron for Overactive Bladder

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 207 (actual)
• Sponsor: Ono Pharmaceutical Co., Ltd. · Industry
• Sex: All
• Age: 20 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

The objective of the study is to evaluate the efficacy and safety of ONO-8577 compared to combination of solifenacin succinate and mirabegron or placebo for overactive bladder

Conditions

• Overactive Bladder

Interventions

Type	Name	Description
DRUG	ONO-8577	Oral administration of ONO-8577 once a daily for 4 weeks
DRUG	solifenacin succinate + mirabegron	Oral administration of solifenacin succinate and mirabegron once a daily for 4 weeks
DRUG	Placebo	Oral administration of Placebo once a daily for 4 weeks

Timeline

• Start date: 2017-04-07
• Primary completion: 2017-08-29
• Completion: 2017-09-26
• First posted: 2017-04-10
• Last updated: 2024-05-03

Locations

30 sites across 1 country: Japan